GB2614166A - T cell receptors recognizing R273C or Y220C mutations in P53 - Google Patents

T cell receptors recognizing R273C or Y220C mutations in P53 Download PDF

Info

Publication number
GB2614166A
GB2614166A GB2304187.4A GB202304187A GB2614166A GB 2614166 A GB2614166 A GB 2614166A GB 202304187 A GB202304187 A GB 202304187A GB 2614166 A GB2614166 A GB 2614166A
Authority
GB
United Kingdom
Prior art keywords
amino acid
acid sequence
seq
polypeptide chain
chain comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB2304187.4A
Other languages
English (en)
Inventor
Kim Sanghyun
Zacharakis Nikolaos
A Rosenberg Steven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of GB2614166A publication Critical patent/GB2614166A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
GB2304187.4A 2020-09-04 2021-09-02 T cell receptors recognizing R273C or Y220C mutations in P53 Pending GB2614166A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063074747P 2020-09-04 2020-09-04
PCT/US2021/048786 WO2022051449A2 (en) 2020-09-04 2021-09-02 T cell receptors recognizing r273c or y220c mutations in p53

Publications (1)

Publication Number Publication Date
GB2614166A true GB2614166A (en) 2023-06-28

Family

ID=77924530

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2304187.4A Pending GB2614166A (en) 2020-09-04 2021-09-02 T cell receptors recognizing R273C or Y220C mutations in P53

Country Status (10)

Country Link
US (1) US20230321240A1 (cg-RX-API-DMAC7.html)
EP (1) EP4208473A2 (cg-RX-API-DMAC7.html)
JP (1) JP7895931B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230066023A (cg-RX-API-DMAC7.html)
CN (1) CN116472050A (cg-RX-API-DMAC7.html)
AU (1) AU2021336399A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191186A1 (cg-RX-API-DMAC7.html)
GB (1) GB2614166A (cg-RX-API-DMAC7.html)
TW (1) TWI900647B (cg-RX-API-DMAC7.html)
WO (1) WO2022051449A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024241888A1 (en) * 2023-03-27 2025-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
WO2026138950A1 (zh) * 2024-12-26 2026-07-02 长春金赛药业有限责任公司 小分子重激活剂化合物在制备治疗抗肿瘤药物中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102585A1 (en) * 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
WO2019036688A1 (en) * 2017-08-18 2019-02-21 Gritstone Oncology, Inc. ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS
WO2019067242A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR SPECIFIC MUTATION OF CANCER P53
WO2019067243A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T CELL RECEPTORS RECOGNIZING P53 MUTE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102585A1 (en) * 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
WO2019036688A1 (en) * 2017-08-18 2019-02-21 Gritstone Oncology, Inc. ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS
WO2019067242A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR SPECIFIC MUTATION OF CANCER P53
WO2019067243A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T CELL RECEPTORS RECOGNIZING P53 MUTE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DREW C. DENIGER ET AL, "T-cell Responses to TP53 & 8220;Hotspot & 8221; Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers", CLINICAL CANCER RESEARCH, 31 May 2018 (2018-05-31), ISSN: 1078-0432, doi:10.1158/1078-0432.CCR-18-0573 abstract *

Also Published As

Publication number Publication date
CN116472050A (zh) 2023-07-21
TW202227477A (zh) 2022-07-16
JP2023540123A (ja) 2023-09-21
TWI900647B (zh) 2025-10-11
WO2022051449A3 (en) 2022-04-14
AU2021336399A9 (en) 2023-07-13
WO2022051449A2 (en) 2022-03-10
KR20230066023A (ko) 2023-05-12
EP4208473A2 (en) 2023-07-12
CA3191186A1 (en) 2022-03-10
US20230321240A1 (en) 2023-10-12
AU2021336399A1 (en) 2023-05-18
JP7895931B2 (ja) 2026-07-28

Similar Documents

Publication Publication Date Title
Salomon et al. Extrajunctional distribution of N-cadherin in cultured human endothelial cells
Fuchs et al. The expression of keratin genes in epidermis and cultured epidermal cells
GB2609760A (en) HLA Class I-restricted T cell receptors against RAS with G12D mutation
Senkevich et al. Domain structure, intracellular trafficking, and β2-microglobulin binding of a major histocompatibility complex class I homolog encoded by molluscum contagiosum virus
GB2610069A (en) HLA class II-restricted T cell receptors against RAS with G12V mutation
JP2022523024A5 (cg-RX-API-DMAC7.html)
CN111875708A (zh) 一种嵌合抗原受体t淋巴细胞及其在制备治疗实体肿瘤的产品中的应用
Otvos Jr et al. Comparison of the effects of amino acid substitutions and β-N-vs. α-O-glycosylation on the T-cell stimulatory activity and conformation of an epitope on the rabies virus glycoprotein
CN113621048A (zh) T细胞抗原受体、其多聚体复合物及其制备方法和应用
JP5189094B2 (ja) 無差別papcd4t細胞エピトープ
US20230212259A1 (en) Yeast display libraries, associated compositions, and associate methods of use
JP2023534241A5 (cg-RX-API-DMAC7.html)
JP2023540123A5 (cg-RX-API-DMAC7.html)
WO2022015694A8 (en) Hla class ii–restricted drb t cell receptors against ras with g12d mutation
Porter et al. Characterization of the atrial natriuretic peptide clearance receptor using a vaccinia virus expression vector.
Nichols et al. A novel splice variant of Pmel17 expressed by human melanocytes and melanoma cells lacking some of the internal repeats
Hughes Evolution of the src-related protein tyrosine kinases
EP4208473A2 (en) T cell receptors recognizing r273c or y220c mutations in p53
Wilson et al. The Onchocerca volvulus homologue of the multifunctional polypeptide protein disulfide isomerase
JP2023535366A5 (cg-RX-API-DMAC7.html)
Isackson et al. Epidermal growth factor binding protein: Identification of a different protein
US8658177B2 (en) Promiscuous HER-2/Neu CD4 T cell epitopes
JP2023535366A (ja) G12v変異を有するrasに対するhlaクラスii拘束性drb t細胞受容体
WO2020257575A1 (en) T-cell receptor for treating fibrolamellar hepatocellular carcinoma
KR101657298B1 (ko) 세포 증식 효과가 증가한 인간 상피세포재생인자 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 및 탄력 개선용 화장료 조성물